Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
185750KOSPI·Feb 04, 2025
Focus on clinical trial plans for CKD-510
Mirae Asset Securities published a company analysis report on Chong Kun Dang Pharmaceutical Corp. (185750) titled "Focus on clinical trial plans for CKD-510".
Summary
Covers Chong Kun Dang Pharmaceutical Corp. (185750).
Covered stock
More on 185750
Limited earnings improvement, but pipeline development on trackMirae Asset Securities · Aug 24, 2026Atrial fibrillation asset newly reflected in pipeline valueMirae Asset Securities · Feb 27, 2026Earnings Stable; R&D Also Steadily in ProgressKB Securities · Nov 04, 2025Focus on the potential of HDAC6 inhibitorMirae Asset Securities · Aug 05, 2025